🇺🇸 LY2605541 in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 10

Most-reported reactions

1. Abasia — 1 report (10%)
2. Anxiety — 1 report (10%)
3. Crying — 1 report (10%)
4. Depression — 1 report (10%)
5. Drug-Induced Liver Injury — 1 report (10%)
6. Fall — 1 report (10%)
7. Femur Fracture — 1 report (10%)
8. Gastric Bypass — 1 report (10%)
9. Haemoglobin Decreased — 1 report (10%)
10. Hip Fracture — 1 report (10%)

Source database →

Frequently asked questions

Is LY2605541 approved in United States?

LY2605541 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for LY2605541 in United States?

Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.